Skip to content

Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices

Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00657397
Acronym
Methaville
Enrollment
197
Registered
2008-04-14
Start date
2009-01-31
Completion date
2011-12-31
Last updated
2012-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C, Methadone, Substance Dependence

Keywords

Methadone, Substance Dependence

Brief summary

The rapid scale up of opioid substitution treatment (OST) for drug users mainly achieved through the possibility of prescribing buprenorphine in primary care has been successful in reducing HIV prevalence among drug users but still inadequate for reducing the spread of HCV. To date, methadone in France can only be initialised in drug centres but GPs can prescribe methadone after stabilisation of dosages. This study was born as an answer to a request from the French Minister of Health that supports the initialisation of methadone in primary care in order to improve coverage by OST (now 70%) in drug users.

Detailed description

We aimed to test the non inferiority of the proportion of non users of street-opioids after one year of treatment in patients inducted in primary care (PC) vs.those inducted in a specialised center for substance dependence (CSAPA). In this multisite, open-label, randomised controlled non-inferiority trial, opioid dependent individuals were randomized to start methadone either in PC or in a CSAPA. After stabilization of methadone dosage (\ 2 weeks), patients could change arm. Follow-up assessments through medical questionnaires and phone interviews was scheduled at month 0 (M0, enrolment) M3, M6, M12. The opiate treatment index (OTI) was used for computing the proportion of patients reporting no use of street opioids in the last month at M12 (primary outcome) in those inducted in PC or in a CSAPA and the non inferiority margins. Primary analysis was by intention to treat (ITT)

Interventions

DRUGMethadone

Methadone sirup once daily

Sponsors

French National Agency for Research on AIDS and Viral Hepatitis
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* 18 to 70 years patients needing methadone for their opioid dependence who are either naives of methadone treatment (prescribed) since at least 1 month * need to switch from buprenorphine to methadone treatment * negative test for pregnancy

Exclusion criteria

* co-dependent on alcohol and benzodiazepines, * inmates, * pregnant women, * individual in irregular situation or who cannot be joined by phone.

Design outcomes

Primary

MeasureTime frame
prevalence of non-users of street opioid after one year of treatment will be compared between arms.one year

Secondary

MeasureTime frame
surveillance of severe adverse events and overdose cases in each armDay -7 to Month 12
Prevalence of non users of street opioids after three months of treatmentthree months
Retention in treatmentone year
Decrease in HCV risk behaviors, addictive behaviors, improvement in quality of life, psychiatric comorbidities, social insertion, reduction in criminal actsone year
cost-effectivenessone year

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026